Document is current
Any future updates will be listed below
-
Authors
Wang, Yingping https://orcid.org/0000-0002-8468-8054
Hennessy, Corinne
Dobrinskikh, Evgenia
Humphries, Stephen M.
Hatakka, Kristina
Ackert-Bicknell, Cheryl L. https://orcid.org/0000-0003-4253-4775
Godfrey, Dana A.
Kelada, Samir N. P. https://orcid.org/0000-0003-2676-9232
Keele, Gregory R. https://orcid.org/0000-0002-1843-7900
Cardwell, Jonathan
Peljto, Anna https://orcid.org/0000-0002-8389-0736
Clouthier, David E. https://orcid.org/0000-0002-2008-477X
Yang, Ivana V.
Schwartz, David A. https://orcid.org/0000-0001-6743-8443
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL149836)
- License Information
-
More Information
Article History
Received: 26 December 2025
Accepted: 30 April 2026
First Online: 12 May 2026
Competing interests
: The authors declare the following competing interests: D.A.S. is the founder and chief scientific officer of Eleven P15, Inc., a company dedicated to the early diagnosis and treatment of pulmonary fibrosis. I.V.Y. is a Consultant for Eleven P15, Inc. The remaining authors declare no competing interests.
